Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Janssens, Ann" or (type exact bookEditor and editor="Janssens, Ann")

Add to list
- Journal Article
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study

Ann Janssens, Zwi N. Berneman, Fritz Offner (UGent) , Sylvia Snauwaert, Philippe Mineur, Gaetan Vanstraelen, Stef Meers, Isabelle Spoormans, Dominique Bron, Isabelle Vande Broek, et al.

(2022) Clinical Hematology International. 4(4). p.133-143
Add to list
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial

Fritz Offner (UGent) , Tadeusz Robak, Ann Janssens, K. Govind Babu, Janusz Kloczko, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Anna Schuh, Andrew Pettitt, et al.

(2020) BRITISH JOURNAL OF HAEMATOLOGY. 190(5). p.736-740
Add to list
- Journal Article
- A1
- open access
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1

Eugen Tausch, Philipp Beck, Richard F. Schlenk, Billy M. C. Jebaraj, Anna Dolnik, Deyan Y. Yosifov, Peter Hillmen, Fritz Offner (UGent) , Ann Janssens, K. Govind Babu, et al.

(2020) HAEMATOLOGICA. 105(10). p.2440-2447
Add to list
- Conference Paper
- C3
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.

Fritz Offner (UGent) , Tadeusz Robak, Ann Janssens, Govind Babu Kanakasetty, Janusz Kloczko, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Anna Schuh, Andrew Pettitt, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(15).
Add to list
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Peter Hillmen, Ann Janssens, K Govind Babu, Janusz Kloczko, Sebastian Grosicki, Stephanie Manson, Astrid McKeown, Ira Gupta, Chai-Ni Chang and Fritz Offner (UGent)

(2016) ACTA ONCOLOGICA. 55(9-10). p.1115-1120
Add to list
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Ian W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, Ann Janssens, Sebastian Grosicki, Wojciech Homenda, Lukas Smolej, Kazimierz Kuliczkowski, Michael Doubek, Natalia Domnikova, et al.

(2016) AMERICAN JOURNAL OF HEMATOLOGY. 91(9). p.900-906
Add to list
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen, Tadeusz Robak, Ann Janssens, K Govind Babu, Janusz Kloczko, Sebastian Grosicki, Michael Doubek, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, et al.

(2015) LANCET. 385(9980). p.1873-1883
Add to list
- Conference Paper
- C3
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL/SLL (RESONATE-2 (TM))

Alessandra Tedeschi, Paul M Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L Bartlett, Jianyong Li, David Simpson, et al.

(2015) BLOOD. 126(23).
Add to list
- Conference Paper
- C3
Gene mutations and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study COMPLEMENT1 (OMB110911)

Eugen Tausch, Christina Galler, Richard Schlenk, Peter Hillmen, Fritz Offner (UGent) , Ann Janssens, K Govindbabu, Jiri Mayer, Sebastian Grosicki, Panagiotis Panagiotidis, et al.

(2014) BLOOD. 124(21).
Add to list
- PhD Thesis
In vitro apoptosis and clonal evolution in chronic lymphocytic leukemia : predictive value and possible influence on treatment

Ann Janssens (UGent)

(2013)
Add to list
- Conference Paper
- C3
Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)

Peter Hillmen, Tadeusz Robak, Ann Janssens, K Govindbabu, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas Boyd, et al.

(2013) BLOOD. 122(21).
Add to list
- Conference Paper
- C3
NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-chi (O-Chl): results from the phase III study complement 1 (OMB110911)

Eugen Tausch, Philipp Beck, Richard F Schlenk, Sabrina Kless, Christina Galler, Peter Hillmen, Fritz Offner (UGent) , Ann Janssens, K Govindbabu, Sebastian Grosicki, et al.

(2013) BLOOD. 122(21).
Add to list
- Conference Paper
- C3
SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study

Jennifer R Brown, Mehdi Hamadani, Jon Arnason, Lionel Karlin, John Hayslip, Nina Wagner-Johnston, Guillaume Cartron, Vincent Ribrag, Sophie de Guibert, Stephen Opat, et al.

(2013) BLOOD. 122(21).
Add to list
High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature

Ann Janssens, Nadine Van Roy (UGent) , Bruce Poppe (UGent) , Lucien Noens (UGent) , Jan Philippé (UGent) , Franki Speleman (UGent) and Fritz Offner (UGent)

(2012) EUROPEAN JOURNAL OF HAEMATOLOGY. 89(1). p.72-80
Add to list
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia

Jerina Boelens (UGent) , Sofie Lust (UGent) , FEMKE VAN BOCKSTAELE, Mireille Van Gele (UGent) , Ann Janssens, Lara Derycke (UGent) , Barbara Vanhoecke (UGent) , Jan Philippé (UGent) , Marc Bracke (UGent) and Fritz Offner (UGent)

(2009) LEUKEMIA RESEARCH. 33(10). p.1335-1343

Academic Bibliography

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study

A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL/SLL (RESONATE-2 (TM))

Gene mutations and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study COMPLEMENT1 (OMB110911)

In vitro apoptosis and clonal evolution in chronic lymphocytic leukemia : predictive value and possible influence on treatment

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)

NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-chi (O-Chl): results from the phase III study complement 1 (OMB110911)

SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study

High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature

Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia

Contents

Support

Contact